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Objective
The authors analyzed the effect of blood transfusions on the pattern of colorectal cancer
recurrence.
Background
Retrospective studies suggest that blood transfusions are associated with a poor prognosis in
patients who undergo operations for colorectal malignancies. In a previously published,
randomized trial, it was investigated whether autologous blood transfusions could overcome this
putative detrimental effect. However, this did not appear to be the case.
Methods
In the current study, the authors analyzed the patterns of recurrence in 420 patients who
underwent curative operations for colorectal cancer.
Results
Patients who did not require transfusions (N = 143) had significantly better disease-free survival
than those who did need transfusions (N = 277); percentages at 4 years were 73% and 59%,
respectively (p = 0.001). No difference was found between both groups in comparing cumulative
percentages of patients having metastases; percentages at 4 years were 25% in the group that
did not undergo transfusion and 27% in the transfused group. The percentage of cases having
local recurrence, however, was significantly increased (p = 0.0006) in the transfused group as
compared with the group that did not undergo transfusion; percentages at 4 years were 20% and
3%, respectively. The groups of patients receiving only allogeneic, only autologous, or both types
of transfusions all had a significantly higher incidence of local recurrence than the patients who
did not receive transfusions, but no differences were found between these three groups.
Conclusions
These findings suggest that the association between blood transfusions and prognosis in
colorectal cancer is a result of the circumstances that necessitate transfusions, leading to the
development of local recurrences, but not of distant metastases.
It has been suggested that allogeneic blood transfu- ysis, combining the evidence of 20 published retrospec-
sions are associated with a poor prognosis of patients tive studies, demonstrated that transfused patients with
who undergo operations for colorectal cancer, possibly colorectal cancer generally had a worse prognosis when
because of immunologic factors. -4 A recent meta-anal- compared with patients who did not undergo transfu-
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sion.5 However, in a randomized trial of 475 patients,
we did not find that patients transfused with autologous
blood had a better prognosis than those patients
transfused with allogeneic blood, although transfused
patients, receiving either type of blood, had a poorer
prognosis than patients who did not receive transfu-
sions.6 Therefore, the circumstances necessitating
transfusions rather than the blood transfusions them-
selves are the real determinant of prognosis. Naturally,
the need for postoperative transfusions was associated
with the amount of blood loss. This might be related to
technical difficulties to resect the tumor, and to surgical
skill.7 These factors also may affect the development of
local recurrence, because local recurrences originate
from remaining viable local tumor residues,8 or local
spill.9 Previous studies reporting on the effects of blood
transfusions on prognosis presented data on survival or
disease-free survival. However, in only a few studies, the
incidence of local recurrence and metastatic disease was
evaluated separately, but did not come to conclusions.'0
In the current study, the relationship between blood
transfusions and the patterns of recurrent disease in pa-
tients participating in the aforementioned trial was in-
vestigated.
METHODS
Those evaluated were patients who underwent cura-
tive operations and participated in a randomized,
multicenter trial to investigate the effect of autologous
blood on prognosis of colorectal cancer as compared
with standard allogeneic transfusions. The design of this
trial has been described in detail elsewhere.6 Briefly, pa-
tients with a potentially curative resection of a colorectal
carcinoma were eligible ifthey fulfilled the criteria set for
autologous blood donation." Patients randomized into
the autologous group had to donate two units ofblood in
two sessions before operation. The collected blood was
separated into packed red cells and fresh frozen plasma.
The transfusion rules were the same for patients in the
autologous group as for patients in the allogeneic group.
Packed red cells were allowed to be given if blood loss
exceeded 500 mL or if the hemoglobin level dropped be-
low 10.5 g/dL.
After standard surgical procedures, the tumors were
staged according to the Turnbull'2 modification of the
original Dukes' classification. A tumor confined to the
bowel wall was staged as Dukes' A; ifthe tumor extended
through the serosa into the pericolic fat, it was staged as
Dukes' B; and if regional lymph nodes contained metas-
tases, it was staged as Dukes' C. En bloc resected tumors
with adjacent organ fixation were not staged as Dukes'
D. No adjuvant chemotherapy was given, and pelvic ra-
diation was only given in a minority ofcases.
A standard follow-up program was used, including his-
tory, physical examination, and laboratory tests, every
3 months during the first 2 years and every 6 months
thereafter. Chest x-ray and colonoscopy were performed
yearly, and ultrasonography ofthe liver was done twice a
year for the first 3 years and once a year thereafter.
If possible, histologic or cytologic evidence was ob-
tained to confirm metastatic or local recurrent disease.
Characteristic changes at physical examination, on x-
ray, on liver ultrasonography, or on computed tomogra-
phy scan also were accepted as metastatic disease or as
local recurrence.
In this study, the incidence of distant metastases and
local recurrence were analyzed as first signs of recurrent
disease. Of the 475 randomized patients, 423 patients
underwent curative surgery. Three of these patients died
from postoperative complications. The remaining 420
patients form the basis of this report.
Incidences implicating cumulative percentages of pa-
tients having metastases and cumulative percentages of
patients having local recurrences were calculated accord-
ing to the Kaplan-Meier method. '3 The log-rank test was
used to compare these estimates. Multivariate analyses
were performed using Cox regression. "4 Two-sided p
value < 0.05 was considered the limit of statistical sig-
nificance.
RESULTS
Patient Characteristics
Of the 420 patients, 214 patients belonged to the allo-
geneic group and 206 to the autologous group. The me-
dian follow-up period ofthe patients was 2.3 years (range
1 to 59 months). No patient was lost to follow-up.
Ofthe 420 patients, 277 received transfusions and 143
patients did not. Ofthese 277 patients, 134 received only
allogeneic transfusions, 101 received only autologous
transfusions, and 42 patients received both types of
transfusions.
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Recurrent Disease
For all studied patients-i.e., whether they received
transfusions or not-the disease-free survival at 4 years
was 66% in the allogeneic group and 63% in the autolo-
gous group (p = 0.93). In the allogeneic group, 54 of214
patients developed recurrent disease (39 distant metasta-
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Table 1. FIRST DETECTED SITE OF
RECURRENT DISEASE ACCORDING TO
RANDOMIZED GROUP
Allogeneic Group Autologous Group
(N = 214) (N = 206)
Total 54 51
Local recurrence 13 20
Metastatic disease 39 30
Liver 23 (59%) 17 (57%)
Lung 5 (13%) 2 (7%)
Brains 2 (5%)
Other 3 (8%) 5 (16%)
Multiple 6 (15%) 6 (20%)
Local and metastatic 2 1
disease
ses, 13 local recurrences, and two patients both simulta-
neously). In the autologous group, 51 of 206 patients de-
veloped recurrent disease (30 distant metastases, 20 local
recurrences, and one patient both). The distribution of
sites of recurrent disease per randomized group is shown
in Table 1.
The disease-free survival at 4 years was 59% in the
group of 277 patients who received transfusions versus
73% in the group of 143 patients who did not require
transfusions (p = 0.001). Using multivariate analysis, al-
lowing for various prognostic factors, blood transfusion
was a significant determinant of disease-free survival.'5
The characteristics of the patients with metastatic dis-
ease and those with local recurrences are shown in Table
2, and the univariate evaluations of different prognostic
factors are reported in Table 3. No statistically significant
differences were found in the cumulative percentages of
distant metastases and of local recurrence in comparing
the randomized groups. The Dukes' classification was a
significant prognostic factor for both endpoints. The
grade of differentiation also was a significant factor for
the incidence of metastases, but in Cox regression analy-
sis, allowing for Dukes' stage, this was not the case. In-
volvement of the rectum, blood loss, and blood transfu-
sions each were related significantly with the incidence of
local recurrence, but not with the incidence of metastatic
disease (Table 3).
Cumulative percentages of metastases comparing the
patients who did not undergo transfusion and the
transfused patients is shown in Figure 1. The percentage
of metastases at 4 years was 25% in the group of patients
who did not undergo transfusion and 27% in the
transfused group. The percentages of metastases did not
differ significantly between the different types of transfu-
sion; at 4 years, the cumulative percentage of metastases
in the group ofpatients receiving only allogeneic transfu-
sions (N = 134), only autologous transfusions (N = 101),
or both types of blood transfusions (N = 42) were 3 1%,
33%, and 14%, respectively. However, the cumulative
percentage oflocal recurrence was significantly less in the
group that did not undergo transfusion as compared with
the groups ofpatients with different types oftransfusions
(Fig. 2). The percentage oflocal recurrence was 3% in the
group that did not undergo transfusion and 20% in the
transfused group (p = 0.0006). The cumulative percent-
ages oflocal recurrence at 4 years in the group ofpatients
receiving only allogeneic transfusions, only autologous
transfusions, or both types of blood transfusions were
20%, 18%, and 23%, respectively, and all were signifi-
cantly higher than the group that did not undergo
transfusion (p = 0.001, 0.02, and < 0.001, respectively).
The percentages of local recurrence of these three
transfused groups of patients did not significantly differ
between each other (p = 0.18).
Multivariate analyses, not allowing for blood loss,
showed that blood transfusion was a significant determi-
nant for local recurrences. This was not the case for me-
tastases (Table 4). When postoperative radiation, given
in a minority of cases (Table 2), also was taken into ac-
Table 2. CHARACTERISTICS OF PATIENTS
WITH METASTATIC DISEASE AND WITH
LOCAL RECURRENCE
Metastatic Local
Total Disease Recurrence
Randomization
Allogeneic group
Autologous group
Age (yrs)
Sex
Male
Female
Operation
Intra-abdominal
Rectal involvement
Dukes' classification
A
B
C
Differentiation
Well
Moderate
Poor
Tumor size (cm)
Adjacent organ fixation
Adjuvant irradiation
Blood loss (mL)
Blood transfusions
No
Yes
214 39 (41)
206 30 (31)
67 67 (67)
242 39 (42)
178 30 (30)
171 30(30)
249 39 (42)
107 2 (2)
165 23 (24)
148 44 (46)
62 6 (7)
311 47 (49)
45 16 (16)
4 4 (4)
32 4 (4)
31 11 (12)
750 900 (900)
143 21(21)
277 48(51)
13 (15)
20 (21)
66 (66)
12 (15)
21 (21)
7 (7)
26 (29)
4 (4)
13 (14)
16 (18)
2 (3)
27 (29)
4 (4)
5 (5)
3 (3)
5 (6)
1300 (1300)
3 (3)
30 (33)
Continuous data are presented as medians categorical data as number of patients.
Adding those patients with both metastatic disease and local recurrence are shown
in parentheses.
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Table 3. UNIVARIATE COMPARISONS OF
PATIENTS HAVING DISTANT METASTASES
AND THOSE HAVING LOCAL RECURRENCE
ACCORDING TO VARIOUS FACTORS
Log Rank Local Log Rank
Metastases* p Value Recurrence* p Value
Randomization
Allogeneic group 27% NS 11% NS
Autologous group 25% 17%
Age (yrs)
<65 27% NS 13% NS
>65 27% 14%
Sex
Male 29% NS 12% NS
Female 22% 16%
Operation
Intra-abdominal 27% NS 7% 0.007
Rectal involvement 25% 19%
Dukes' classification
A 2% <0.0001 7% 0.004
B 23% 10%
C 49% 27%
Differentiation
Well 20% 0.0006 7% NS
Moderate 24% 14%
Poor 49% 25%
Tumor size (cm)
<5 26% NS 13% NS
.5 26% 16%
Adjacent organ fixation
No 27% NS 14% NS
Yes 13% 8%
Blood loss (mL)
<500 23% NS 4% 0.001
>500 and <1000 28% 14%
> 1000 28% 24%
Blood transfusions
No 25% NS 3% 0.0006
Yes 27% 20%
Cumulative percentages at 4 years, according to Kaplan-Meier estimates.
count in these regression models, the estimates and p val-
ues did not change appreciably, and irradiation was not
an additional prognostic factor. When blood loss in the
multivariate analysis was taken into consideration, the
impact ofblood transfusions on the local recurrence rate
was no longer statistically significant (Table 4).
To explore the effect on prognosis of preoperative au-
tologous donation itself, only the patients who did not
undergo transfusion were evaluated. Comparison of
those patients in the allogeneic group (N = 94) with those
in the autologous group (N = 49) showed no significant
differences in disease-free survival (75% vs. 69%), per-
centage ofdistant metastases (23% vs. 29%), and percent-
age of local recurrence (3% vs. 2%).
DISCUSSION
Blood transfusions seem to be associated with poor
prognosis of colorectal cancer. This relationship ap-
peared not to be causal; rather, the circumstances that
necessitate transfusions are of prognostic importance in
colorectal cancer patients.6 Ofall studies reporting on re-
current disease from colorectal cancer and blood transfu-
sions, only a few made a distinction between local recur-
rence and metastatic disease in the analyses. So far, no
additional information has been given about the nega-
tive association between blood transfusions and progno-
SiS.
The current study shows that the relationship between
blood transfusions and the increased risk of recurrent
disease is a result ofan increased risk oflocal recurrences.
No relation was found with the incidence of distant me-
tastases. Similar findings applied to the amount ofblood
loss, but evaluating blood loss and transfusions simulta-
neously by multivariate analysis made the significance of
either factor disappear. This is a consequence of the
strong relationship that existed between blood loss and
transfusion because of our transfusion rules (median
blood loss in case of no transfusion was 390 mL; in case
oftransfusion 1050 mL; p < 0.001). The only other prog-
nostic factor affecting local recurrence and not meta-
static disease was an operation of a rectal tumor, com-
pared with an intra-abdominal tumor. Although resec-
tions of rectal tumors are associated with larger amounts
of blood loss and therefore, require more transfusions,
multivariate analysis showed blood transfusion to be an
independent factor of prognosis. In addition, there are
studies restricted to colonic cancer that found a detri-
mental effect of blood transfusions, too."' In the cur-
rent study, we found that the influence of rectal involve-
ment was not additional to the effect of blood transfu-
sions in multivariate analysis. In our patient population,
the incidence of rectal involvement was relatively high,
which is caused by our inclusion criteria. All patients
should be able to donate blood and therefore, must have
a hemoglobin level of at least 1 1.3 g/dL (7 mmol/L). Pa-
tients with tumors in the right colon often have had ane-
mia or transfusions preoperatively and are (in both situ-
ations) ineligible for our study.
In this study, only three patients had both local recur-
rence and metastatic disease at the moment recurrent
disease was diagnosed. In retrospective studies, this num-
ber usually was higher, which probably can be explained
by the prospective design of our study and our intensive
follow-up program, in which examinations such as liver
ultrasonography were performed routinely.
From the moment recurrent disease was detected, the
median survival time was similar in patients who had
local recurrences and those who had distant metastases.
Thus, a detrimental prognostic relationship between
transfusions and the development of local recurrence
will have a comparable effect on survival. The retrospec-
tive studies reporting on the effect of blood transfusions
and cancer survival might, therefore, be explained by a
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Figure 1. Cumulative percentages of
patients having distant metastases ac-
cording to transfusions received. The
group of patients receiving only alloge-
neic transfusions (allo; N = 134), only
autologous transfusions (auto; N =
101), and both types of transfusions
(both; N = 42) are all not significantly
different from the patients who did not
undergo transfusion (none; N = 143).
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Figure 2. Cumulative percentages of
patients having local recurrence ac-
cording to transfusions received. The
group of patients receiving only alloge-
neic transfusions (allo; N = 134), only
autologous transfusions (auto; N =
101), and both types of transfusions
(both; N = 42) are all significantly
different from the patients who did not
undergo transfusion (none; N = 143).
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Table 4. MULTIVARIATE ANALYSIS OF
THE INCIDENCE OF METASTASES AND
LOCAL RECURRENCE
Relative
Relative Local
Metastases Recurrence
Factor Rate p Value Rate p Value
Blood transfusions
No 1 1
Yes 1.6 NS 5.2* 0.008
Dukes' stage
A 1 1
B 7.6 0.006 2.2 NS
C 23.8 <0.001 5.1 0.004
Operation
Intra-abdominal 1 1
Rectal involvement 1.0 NS 2.0 NS
This estimate is 3.5 (p = 0.06) when in the analysis also blood loss was taken into
account (relative local recurrence rate = 1.3 as compared with 50% lower amount
of blood loss; p = 0. 14). The addition of blood loss did not appreciably change the
other estimates or their p values.
57% for transfused patients. In a recent meta-analysis5
representing over 5000 patients, a relationship between
blood transfusions and poor prognosis was reported of
the same magnitude as found in our study. Unfortu-
nately, in those studies, there were no data available on
the incidence of local recurrence and the incidence of
metastatic disease separately.
The fact that local recurrence represents failure of the
surgical technique is demonstrated by McArdle and
Hole,'9 who reported on the variability among surgeons
on postoperative complications and ultimate survival. It
has been suggested that a more meticulous and careful
dissection of the pararectal tissues reduces the incidence
of local recurrence for rectal tumors.20 Recently, the re-
sults of total mesorectal excision for rectal cancer were
reported and showed that such surgery gave better dis-
ease-free survival than other studies had demonstrated
using adjuvant radiation or chemotherapy.21'22
Another explanation of the current findings might be
the presence ofgrowth factors released from platelets af-
ter blood loss in the peritoneal cavity. An enhanced peri-
toneal tumor load was found in rats receiving serum in-
traperitioneally as compared with those that did not re-
ceive it.23 However, the rate of liver metastases also was
increased in this animal model.
The current study shows that the prognostic associa-
tion between blood transfusions and colorectal cancer is
mainly a result of an increased risk of local recurrences
and not an increased risk of metastatic disease. Assum-
ing that local recurrence and the need for blood transfu-
sions are related to surgical difficulties and skill, opera-
tions on patients with colorectal cancer should be per-
formed in a meticulous way, with precise tumor excision
and as few transfusions as necessary.
Ann. Surg. * December 1994
Therefore, patients who are scheduled for potentially
curative resections of colorectal malignancies may have
better prognoses if their surgeries are performed by
surgeons who are experienced in colorectal cancer sur-
gery.
Acknowledgments
The authors thank M.A.W. Hoynck van Papendrecht, Ph.D., for co-
ordinating this trial for many years, and the principle investigators of
the participating centers for enrollment of the patients: R. U. Boel-
houwer, Ph.D., Ikazia Ziekenhuis, Rotterdam; E. D. M. Bruggink,
Ph.D., Canisius-Wilhelmina Ziekenhuis, Nijmegen; C. J. van Duin,
M.D., De Wever Ziekenhuis, Heerlen; J. J. Jakimowicz, Ph.D., Catha-
rina Ziekenhuis, Eindhoven; C. K. Jongsma, Ph.D., Havenziekenhuis,
Rotterdam; B. L. A. M. Langenhorst, M.D., Academisch Ziekenhuis
Dijkzigt, Rotterdam; F. T. T. Liem, M.D., Carolus Ziekenhuis, Den
Bosch; W. S. Meijer, Ph.D., St. Clara Ziekenhuis, Rotterdam; J. J. Petit,
Ph.D., Zeeweg Ziekenhuis, IJmuiden; K. M. Rigg, M.D., Medical
School, University of Newcastle Upon Tyne, United Kingdom; M. K.
M. Salu, Ph.D., Zuiderziekenhuis, Rotterdam; Th. J. van Straaten,
Ph.D., St. Joseph Ziekenhuis, Veldhoven; B. C. de Vries, Ph.D., Wes-
teinde Ziekenhuis, Den Haag; W. F. Weidema, Ph.D., Reinier de Graaf
Gasthuis, Delft; and J. C. J. Wereldsma, Ph.D., St. Franciscus Zieken-
huis, Rotterdam.
References
1. Gantt CL. Red blood cells for cancer patients. Lancet 1981; 2:363.
2. Burrows L, Tartter P. Effect of blood transfusions on colonic ma-
lignancy recurrence rate. Lancet 1982; 2:662.
3. Francis DMA. Relationship between blood transfusion and tu-
mour behaviour. Br J Surg 1991; 78:1420-1428.
4. Blumberg N, Heal JM. Transfusion and host defences against can-
cer recurrence and infection. Transfusion 1989; 29:236-245.
5. Chung M, Steinmetz OK, Gordon PH. Perioperative blood
transfusion and outcome after resection for colorectal carcinoma.
BrJ Surg 1993; 80:427-432.
6. Busch ORC, Hop WCJ, Hoynck van Papendrecht MAW, et al.
Blood transfusions and prognosis in colorectal cancer. N Engl J
Med 1993; 328:1372-1376.
7. Phillips RKS, Hittinger R, Blesovsky L, et al. Local recurrence fol-
lowing 'curative' surgery for large bowel cancer: I. the overall pic-
ture. BrJ Surg 1984; 71:12-16.
8. Heald RJ, Ryall RDH. Recurrence and survival after mesorectal
excision for rectal cancer. Lancet 1986; 1: 1479-1482.
9. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of
rectal adenocarcinoma due to inadequate surgical resection: histo-
pathological study of lateral tumour spread and surgical excision.
Lancet 1986; 2:996-998.
10. Cheslyn-Curtis S, Fielding LP, Hittinger R, et al. Large bowel can-
cer: the effect of perioperative blood transfusion on outcome. Ann
R Coll Surg Engl 1990; 72:53-59.
11. Council on Scientific Affairs. Autologous blood transfusion.
JAMA 1986; 256:2378-2380.
12. Turnbull RB, Kyle K, Watson FR, Spratt J. Cancer of the colon:
the influence of the no-touch isolation technic on survival rates.
Ann Surg 1967; 166:420-425.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete
observations. J Am Stat Assoc 1958; 53:457-481.
14. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972;
34:187-202.
15. Busch ORC, Hop WCJ, Marquet RL, Jeekel J. Prognostic impact
Vol. 220 e No. 6
of blood transfusions on disease-free survival in colorectal carci-
noma. Scand J Gastroenterol 1993; 28 Suppl 200:21-23.
16. Agarwal M, Blumberg N. Colon cancer patients transfused periop-
eratively have an increased incidence of recurrence. Transfusion
1983; 23:42 1.
17. Voogt PJ, van de Velde CJH, Brand A, et al. Perioperative blood
transfusion and cancer prognosis: different effects ofblood transfu-
sion on prognosis ofcolon and breast cancer patients. Cancer 1987;
59:836-843.
18. Tartter PI. The association ofperioperative blood transfusion with
colorectal cancer recurrence. Ann Surg 1992; 216:633-638.
19. McArdle CS, Hole D. Impact of variability among surgeons on
Blood Transfusion and Colorectal Cancer 797
postoperative morbidity and mortality and ultimate survival. Br
Med J 199 1; 302:1501-1505.
20. Cawthorn SJ, Parums DV, Gibbs NM, et al. Extent of mesorectal
spread and involvement of lateral resection margin as prognostic
factors after surgery for rectal cancer. Lancet 1990; 335:1055-
1059.
21. Heald RJ, Karanjia ND. Results of radical surgery for rectal can-
cer. World J Surg 1992; 16:848-857.
22. MacFarlane JK, Ryall RDH, Heald RJ. Mesorectal excision for
rectal cancer. Lancet 1993; 341:457-460.
23. Lawrance RJ, Cooper AJ, Loizidou M, et al. Blood transfusion and
recurrence of colorectal cancer: the role of platelet derived growth
factors. Br J Surg 1990; 77:1106-1109.
